The global Human Insulin market was valued at USD 26.64 billion in 2016 and is projected to reach USD 57.40 billion by 2025, growing at a CAGR of 7.98% from 2017 to 2025.
Human insulin is the name which describes synthetic insulin which is laboratory grown to mimic the insulin in humans. The Number of diabetic patients is increasing including young population too. The rising need of treatment is expected to boost the market for synthetic insulin in the forecast period.
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 High Number of Diabetic Patients
1.2 Rising Market Demand for HI Analogs
1.3 Technological Advancements
1.4 Favorable Medical Reimbursement Scenario
2. Market Restraints
2.1 Stringent regulatory framework
Market Segmentation:
1. By Application:
1.1 Type I Diabetes
1.2 Type II Diabetes
2. By Delivery Devices:
2.1 Syringes
2.2 Pens
2.2.1 Disposable Pens
2.2.2 Reusable Pens
2.3 Pen Needles
2.3.1 Standard Pen Needles
2.3.2 Safety Pen Needles
3. By Brand:
3.1 HI Analogs and Biosimilars
3.1.1 Lantus
3.1.2 Novorapid and Novolog
3.1.3 Humalog
3.1.4 Other Brands
3.2 HI Biologics
3.2.1 Actrapid, Mixtard, and Insulatard
3.2.2 Humulin
3.2.3 Insuman
4. By Type:
4.1 Insulin Analogs and Biosimilars
4.1.1 Long-Acting Biosimilars
4.1.2 Rapid-Acting Biosimilars
4.1.3 Premixed Biosimilars
4.2 HI Biologics
4.2.1 Short-Acting Biologics
4.2.2 Intermediate-Acting Biologics
4.2.3 Premixed Biologics
5. By Product Type:
5.1 HI Drugs
5.2 HI Delivery Devices
6. By Region:
6.1 North America (U.S., Canada, Mexico)
6.2 Europe (Germany, UK, France, Rest of Europe)
6.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
6.4 Latin America (Brazil, Argentina, Rest of Latin America)
6.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. B. Braun Melsungen AG
2. Becton, Dickinson and Company
3. Biocon Limited
4. Biodel Inc.
5. ELI Lilly and Company
6. Julphar (Also Known as Gulf Pharmaceutical Industries)
7. NOVO Nordisk A/S
8. Sanofi
9. Wockhardt Limited
10. Ypsomed AG
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the Human Insulinmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL HUMAN INSULINMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL HUMAN INSULINMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL HUMAN INSULIN MARKET, BY APPLICATION:
5.1 Type I Diabetes
5.2 Type II Diabetes
6 GLOBAL HUMAN INSULIN MARKET, BY DELIVERY DEVICES:
6.1 Syringes
6.2 Pens
6.2.1 Disposable Pens
6.2.2 Reusable Pens
6.3 Pen Needles
6.3.1 Standard Pen Needles
6.3.2 Safety Pen Needles
7 GLOBAL HUMAN INSULIN MARKET, BY BRAND:
7.1 HI Analogs and Biosimilars
7.1.1 Lantus
7.1.2 Novorapid and Novolog
7.1.3 Humalog
7.1.4 Other Brands
7.2 HI Biologics
7.2.1 Actrapid, Mixtard, and Insulatard
7.2.2 Humulin
7.2.3 Insuman
8 GLOBAL HUMAN INSULIN MARKET, BY TYPE:
8.1 Insulin Analogs and Biosimilars
8.1.1 Long-Acting Biosimilars
8.1.2 Rapid-Acting Biosimilars
8.1.3 Premixed Biosimilars
8.2 HI Biologics
8.2.1 Short-Acting Biologics
8.2.2 Intermediate-Acting Biologics
8.2.3 Premixed Biologics
9 GLOBAL HUMAN INSULIN MARKET, BY PRODUCT TYPE:
9.1 HI Drugs
9.2 HI Delivery Devices
10 GLOBAL HUMAN INSULINMARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025
11 GLOBAL HUMAN INSULINMARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies
12 COMPANY PROFILES
12.1 B. Braun Melsungen AG
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments
12.2 Becton, Dickinson and Company
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments
12.3 Biocon Limited
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments
12.4 Biodel Inc.
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments
12.5 ELI Lilly and Company
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments
12.6 Julphar (Also Known as Gulf Pharmaceutical Industries)
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments
12.7 NOVO Nordisk A/S
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments
12.8 Sanofi
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments
12.9 Wockhardt Limited
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Development
12.10 Ypsomed AG
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Development
13 Appendix
13.1 Related Reports
The 3D Digital Human Technology Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, manufac...
Market Overview
The Asia Pacific Digital Asset Management (DAM) Market is poised for substantial growth from 2024 to 2034, driven by the increasing need for efficient digital content management and the growing importance of digital assets across various business functions. The market is...
Market Overview
The Europe Digital Asset Management (DAM) Market is poised for significant growth from 2024 to 2034, driven by increasing digitalization, the need for efficient asset management, and the growing importance of content in various business functions. The market is projected...
Market Overview
The North America Digital Asset Management (DAM) Market is expected to experience significant growth from 2024 to 2034, driven by the increasing need for efficient management of digital assets, the growing adoption of cloud-based solutions, and the rising importance of d...
Market Overview
The Global Digital Asset Management Market is poised to experience significant growth over the next decade, fueled by the increasing need for efficient management of digital assets, the rise of digital marketing, and the adoption of cloud-based solutions. As of 2024, the...
Market Overview
The Asia Pacific SCADA (Supervisory Control and Data Acquisition) Market is on a trajectory of robust growth from 2024 to 2034. This expansion is driven by advancements in industrial automation, increasing demand for real-time data monitoring and control, and the integra...
Market Overview
The Europe SCADA (Supervisory Control and Data Acquisition) Market is poised for substantial growth from 2024 to 2034, driven by increasing automation across industrial sectors and the need for real-time data acquisition and process control. The market is projected to ac...
Market Overview
The North America SCADA (Supervisory Control and Data Acquisition) Market is anticipated to witness robust growth from 2024 to 2034, driven by the increasing demand for automation, the need for real-time monitoring, and the expansion of smart grid initiatives. By 2034, t...
Market Overview
The Global SCADA (Supervisory Control and Data Acquisition) Market is poised for robust growth from 2024 to 2034, driven by the increasing adoption of automation and digitalization across various industries. Valued at USD XX.XX billion in 2024, the market is expected to ...
The Human Rabies Vaccine Antibody Testing Service Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive ...